Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd
Shenzhen Stock ExchangeTotal Valuation
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd carries a market capitalization of 2.99B, placing it among publicly traded companies globally. Its enterprise value stands at 1.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.99B |
| Enterprise Value | 1.93B |
Share Statistics
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd currently has 106.28M shares outstanding.
| Shares Outstanding | 106.28M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd trades at a trailing price-to-earnings ratio of 24.39. The price-to-sales ratio is 2.70, and the price-to-book ratio stands at 3.70.
| PE Ratio | 24.39 |
| PS Ratio | 2.70 |
| PB Ratio | 3.70 |
| P/TBV Ratio | 1.82 |
| P/FCF Ratio | 41.15 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd trades at an EV/EBITDA multiple of 14.96 and an EV/FCF ratio of 26.54. The EV/Sales ratio of 1.77 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.96 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.77 |
| EV / EBITDA | 14.96 |
| EV / EBIT | 14.96 |
| EV / FCF | 26.54 |
Financial Position
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd maintains a current ratio of 3.82, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.08, indicating elevated leverage, while an interest coverage ratio of 94.31 demonstrates strong ability to service its debt obligations.
| Current Ratio | 3.82 |
| Quick Ratio | 2.40 |
| Debt / Equity | 9.08 |
| Debt / EBITDA | 1.17 |
| Interest Coverage | 94.31 |
Financial Efficiency
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd posts a return on equity of 15.97 and a return on invested capital of 6.29.
| Return on Equity (ROE) | 15.97 |
| Return on Assets (ROA) | 5.27 |
| Return on Invested Capital (ROIC) | 6.29 |
| Return on Capital Employed (ROCE) | 13.43 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 5.29 |
Taxes
Over the trailing twelve months, Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd has paid 18.88M in income taxes, reflecting an effective tax rate of 13.55.
| Income Tax | 18.88M |
| Effective Tax Rate | 13.55 |
Stock Price Statistics
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's stock has declined approximately -2.36357% over the past 52 weeks. The 50-day moving average sits at 28.76, while the 200-day moving average is 32.26.
| Beta (5Y) | N/A |
| 52-Week Price Change | -2.36357% |
| 50-Day Moving Average | 28.76 |
| 200-Day Moving Average | 32.26 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd generated 1.09B in revenue and converted that into 120.75M in net income, yielding earnings per share of 1.16. EBITDA reached 129.12M, while operating income came in at 129.12M.
| Revenue | 1.09B |
| Gross Profit | 601.26M |
| Operating Income | 129.12M |
| Pretax Income | 139.34M |
| Net Income | 120.75M |
| EBITDA | 129.12M |
| EBIT | 129.12M |
| Earnings Per Share (EPS) | 1.16 |
Balance Sheet
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd holds 1.17B in cash and equivalents against 151.28M in total debt, resulting in a net debt position of -1.02B. Total book value stands at 794.83M, with working capital of 1.37B providing operational flexibility.
| Cash & Cash Equivalents | 1.17B |
| Total Debt | 151.28M |
| Net Debt | -1.02B |
| Equity (Book Value) | 794.83M |
| Book Value Per Share | 7.63 |
| Working Capital | 1.37B |
Cash Flow
After subtracting -71.56M in capital expenditures, free cash flow totaled -71.56M - equivalent to -0.69 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -71.56M |
| Free Cash Flow | -71.56M |
| FCF Per Share | -0.69 |
Margins
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd operates with a gross margin of 55.03, reflecting its pricing power and cost economics. The operating margin of 11.82 and net profit margin of 11.05 provide insight into operational efficiency.
| Gross Margin | 55.03 |
| Operating Margin | 11.82 |
| Pretax Margin | 12.75 |
| Profit Margin | 11.05 |
| EBITDA Margin | 11.82 |
Dividends & Yields
The company's payout ratio of 27.01 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.31 |
| Dividend Yield | N/A |
| Payout Ratio | 27.01 |
| Shareholder Yield | 1.17 |
| FCF Yield | 2.43 |
Scores
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd posts an Altman Z-Score of 4.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.32 |